150 related articles for article (PubMed ID: 38291735)
1. No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCC.
Copil FD; Campani C; Lequoy M; Sultanik P; Blaise L; Wagner M; Ganne-Carrié N; Ozenne V; Thabut D; Nault JC; Ratziu V; Allaire M
Liver Int; 2024 Apr; 44(4):931-943. PubMed ID: 38291735
[TBL] [Abstract][Full Text] [Related]
2. Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab.
Campani C; Bamba-Funck J; Campion B; Sidali S; Blaise L; Ganne-Carrié N; Demory A; Sutter O; Larrey E; Evain M; Ghannouchi H; Wagner M; Marra F; Sutton A; Allaire M; Nault JC
Liver Int; 2023 Mar; 43(3):708-717. PubMed ID: 36444741
[TBL] [Abstract][Full Text] [Related]
3. Enhanced therapeutic outcomes with atezolizumab-bevacizumab and SIRT combination compared to SIRT alone in unresectable HCC: A promising approach for improved survival.
Mejait A; Roux C; Soret M; Larrey E; Wagner M; Bijot JC; Lussey-Lepoutre C; Thabut D; Goumard C; Maksud P; Allaire M
Clin Res Hepatol Gastroenterol; 2024 Feb; 48(2):102282. PubMed ID: 38191073
[TBL] [Abstract][Full Text] [Related]
4. Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study.
Kudo M; Finn RS; Cheng AL; Zhu AX; Ducreux M; Galle PR; Sakamoto N; Kato N; Nakano M; Jia J; Vogel A
Liver Cancer; 2023 Oct; 12(5):479-493. PubMed ID: 37901766
[TBL] [Abstract][Full Text] [Related]
5. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.
Rimini M; Rimassa L; Ueshima K; Burgio V; Shigeo S; Tada T; Suda G; Yoo C; Cheon J; Pinato DJ; Lonardi S; Scartozzi M; Iavarone M; Di Costanzo GG; Marra F; Soldà C; Tamburini E; Piscaglia F; Masi G; Cabibbo G; Foschi FG; Silletta M; Pressiani T; Nishida N; Iwamoto H; Sakamoto N; Ryoo BY; Chon HJ; Claudia F; Niizeki T; Sho T; Kang B; D'Alessio A; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimur T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y; Pedica F; De Cobelli F; Ratti F; Aldrighetti L; Kudo M; Cascinu S; Casadei-Gardini A
ESMO Open; 2022 Dec; 7(6):100591. PubMed ID: 36208496
[TBL] [Abstract][Full Text] [Related]
6. Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab.
Sultanik P; Campani C; Larrey E; Campion B; Evain M; Roux C; Blaise L; Wagner M; Rudler M; Nault JC; Thabut D; Allaire M
Dig Liver Dis; 2024 Mar; ():. PubMed ID: 38548580
[TBL] [Abstract][Full Text] [Related]
7. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
[TBL] [Abstract][Full Text] [Related]
8. Extent to which weight loss contributes to improving metabolic dysfunction-associated and metabolic and alcohol related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups.
Fukuda T; Okamoto T; Fukaishi T; Kawakami A; Tanaka M; Yamada T; Monzen K
Front Endocrinol (Lausanne); 2024; 15():1392280. PubMed ID: 38779448
[TBL] [Abstract][Full Text] [Related]
9. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study.
Fulgenzi CAM; Cheon J; D'Alessio A; Nishida N; Ang C; Marron TU; Wu L; Saeed A; Wietharn B; Cammarota A; Pressiani T; Personeni N; Pinter M; Scheiner B; Balcar L; Napolitano A; Huang YH; Phen S; Naqash AR; Vivaldi C; Salani F; Masi G; Bettinger D; Vogel A; Schönlein M; von Felden J; Schulze K; Wege H; Galle PR; Kudo M; Rimassa L; Singal AG; Sharma R; Cortellini A; Gaillard VE; Chon HJ; Pinato DJ
Eur J Cancer; 2022 Nov; 175():204-213. PubMed ID: 36148739
[TBL] [Abstract][Full Text] [Related]
10. Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
Fukushima T; Morimoto M; Kobayashi S; Ueno M; Uojima H; Hidaka H; Kusano C; Chuma M; Numata K; Tsuruya K; Arase Y; Kagawa T; Hattori N; Ikeda H; Watanabe T; Tanaka K; Maeda S
Oncologist; 2023 Jul; 28(7):e526-e533. PubMed ID: 37023703
[TBL] [Abstract][Full Text] [Related]
11. Metabolic dysfunction-associated steatotic liver disease increases hepatocellular carcinoma risk in chronic hepatitis B patients: a retrospective cohort study.
Lin M; Gao B; Peng M; Chen X; Xiao H; Shi M; Zhang X; Zeng F; Chi X
Front Physiol; 2024; 15():1347459. PubMed ID: 38405121
[No Abstract] [Full Text] [Related]
12. The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing.
Köstek O; Demirel A; Hacıoğlu MB; Tastekin D; Karabulut S; Gündogdu A; Sever N; Ayhan M; Çelebi A; Majidova N; Yaşar A; Ağyol Y; Erel P; Kocaaslan E; Güren AK; Arıkan R; Isık S; Ercelep O; Goksu SS; Alandag C; Bilgetekin İ; Caner B; Sahin AB; Gulmez A; Akagunduz B; Kose F; Kaplan MA; Dogan E; Sakalar T; Guven DC; Gurbuz M; Ergun Y; Karaagac M; Turker S; Ozkul O; Yıldız B; Sahin S; Demiray AG; Sari M; Erdogan B; Hacıbekiroglu İ; Çakmak Öksüzoğlu ÖB; Kilickap S; Bilici A; Bayoglu İV; Topaloglu S; Cicin İ
J Chemother; 2024 Jan; ():1-9. PubMed ID: 38263804
[TBL] [Abstract][Full Text] [Related]
13. Outcome of Atezolizumab Plus Bevacizumab Combination Therapy in High-Risk Patients with Advanced Hepatocellular Carcinoma.
Hwang SY; Woo HY; Heo J; Kim HJ; Park YJ; Yi KY; Lee YR; Park SY; Chung WJ; Jang BK; Tak WY
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398229
[TBL] [Abstract][Full Text] [Related]
14. Cardiometabolic risk factors in MASLD patients with HCC: the other side of the coin.
Meroni M; Longo M; Dongiovanni P
Front Endocrinol (Lausanne); 2024; 15():1411706. PubMed ID: 38846491
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis.
Brown TJ; Mamtani R; Gimotty PA; Karasic TB; Yang YX
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2345-2354. PubMed ID: 36862158
[TBL] [Abstract][Full Text] [Related]
16. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study.
Yau T; Kaseb A; Cheng AL; Qin S; Zhu AX; Chan SL; Melkadze T; Sukeepaisarnjaroen W; Breder V; Verset G; Gane E; Borbath I; Rangel JDG; Ryoo BY; Makharadze T; Merle P; Benzaghou F; Milwee S; Wang Z; Curran D; Kelley RK; Rimassa L
Lancet Gastroenterol Hepatol; 2024 Apr; 9(4):310-322. PubMed ID: 38364832
[TBL] [Abstract][Full Text] [Related]
17. Atezolizumab Plus Bevacizumab in Advanced HCC: Efficacy in NASH-Specific Etiology.
Llovet JM; Heikenwalder M
Gastroenterology; 2023 Nov; 165(5):1308-1310. PubMed ID: 37116832
[No Abstract] [Full Text] [Related]
18. Impact of metabolic dysfunction-associated steatotic liver disease on the efficacy of immunotherapy in patients with chronic hepatitis B-related hepatocellular carcinoma.
Han J; Kuai W; Yang L; Tao X; Wang Y; Zeng M; Li Y; Mi Y; Zhang N; Lu W; Xu L
Cancer Biol Med; 2024 May; ():. PubMed ID: 38712819
[TBL] [Abstract][Full Text] [Related]
19. Albumin infusion reduces ascite occurrence in Child-Pugh B patients treated by Atezolizumab-Bevacizumab for advanced HCC.
Chaibi S; Larrey E; Couty JP; Sultanik P; Campani C; Blaise L; Wagner M; Desdouets C; Nault JC; Thabut D; Allaire M
Clin Res Hepatol Gastroenterol; 2023 Oct; 47(8):102199. PubMed ID: 37666414
[TBL] [Abstract][Full Text] [Related]
20. Metabolic management after sustained virologic response in elderly patients with hepatitis C virus: A multicenter study.
Sano T; Amano K; Ide T; Isoda H; Honma Y; Morita Y; Yano Y; Nakamura H; Itano S; Miyajima I; Shirachi M; Kuwahara R; Ohno M; Kawaguchi T; Tsutsumi T; Nakano D; Arinaga-Hino T; Kawaguchi M; Eguchi Y; Torimura T; Takahashi H; Harada M; Kawaguchi T;
Hepatol Res; 2024 Apr; 54(4):326-335. PubMed ID: 37975277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
